Could a simple blood test help identify the earliest warning signs of ovarian cancer, even before invasive cancer develops? Researchers have discovered a molecular signal in the blood that could help detect microscopic precancerous changes linked to ovarian cancer. This breakthrough could open new possibilities for earlier diagnosis and prevention, particularly among women at high genetic risk.
Blood Test Identifies an Early Warning Signal
The study, published in the journal Nature Medicine, identified elevated levels of an RNA molecule called Tu-Stroma in women with a precancerous condition known as serous tubal intraepithelial carcinoma (STIC).
Ovarian cancer, particularly high-grade serous ovarian cancer, often begins with microscopic changes in the lining of the fallopian tubes. These abnormal cells can develop into cancer over time but are difficult to detect through conventional screening methods. Unlike traditional approaches that focus on identifying smaller tumours, the new blood test aims to detect molecular changes that occur before invasive cancer develops.
Study Shows Promising Detection Accuracy
Researchers found that measuring Tu-Stroma levels in blood samples helped identify STIC in 92.3% of affected women. The test also correctly identified 98.2% of healthy women.
Furthermore, among women with inherited genetic risk factors for ovarian cancer, approximately 72% of positive results were accurate, while negative results were correct nearly 100% of the time, according to the study. These findings suggest that the molecular marker could help identify women who may have precancerous changes and require closer medical evaluation.
Potential Benefits for Women at High Risk
The discovery could be particularly important for women with inherited risk factors for ovarian cancer, who often face difficult decisions about preventive surgery to remove their fallopian tubes and ovaries.
Currently, doctors largely base these decisions on inherited genetic risk rather than confirming whether precancerous lesions are actually present. The new blood test could eventually provide additional biological information to support these decisions.
However, researchers emphasise that further studies are necessary before the test can become part of routine clinical practice. Prospective clinical studies will help establish how reliably it detects precancerous changes and whether it can guide prevention strategies.
The findings offer a promising direction for ovarian cancer research, potentially shifting the focus from detecting established tumours to identifying early molecular warning signs before the disease becomes invasive. As reported by ET Healthworld, the discovery could pave the way for earlier ovarian cancer detection and more informed prevention strategies, especially for women at high risk.